CDSCO Tightens Oversight on GLP-1 Weight-Loss Drugs Amid Misuse Concerns

The Central Drugs Standard Control Organisation (CDSCO) has intensified oversight of GLP-1-based weight-loss drugs across India as reported by CNBC TV18. The move follows reports of unauthorised sales and misuse of these prescription medicines across multiple channels.

Inspections were conducted across online pharmacies, wholesalers, retailers, and wellness clinics. The regulator has initiated enforcement steps to address compliance gaps and strengthen monitoring of distribution practices.

Inspection Findings and Regulatory Action

The CDSCO conducted inspections at 49 entities spanning different points in the supply chain. These included online platforms, physical pharmacies, wholesalers, and wellness clinics involved in drug distribution.

Authorities identified irregularities related to unauthorised sales and non-compliant promotional activities. Notices have been issued, and entities have been warned of stricter regulatory action in case of continued violations.

Rising Availability of Generic Variants

The entry of multiple generic variants has significantly expanded the availability of GLP-1-based drugs in the Indian market. These medicines are now widely accessible through retail pharmacies, online platforms, and wellness clinics.

Officials noted that increased availability has enabled on-demand access without proper prescriptions in some cases. This trend has raised concerns regarding enforcement of prescription-only requirements.

Safety Concerns and Medical Advisory

Health authorities have highlighted the risks associated with the unsupervised use of GLP-1-based drugs. These medicines, when used without proper clinical guidance, may lead to serious adverse effects and health complications.

The ministry has emphasised that such drugs should only be used under the supervision of qualified medical practitioners. It reiterated that patient safety remains central to regulatory oversight and enforcement actions.

Advisory on Promotion and Advertising

On March 10, 2026, a comprehensive advisory was issued to manufacturers of GLP-1-based drugs. The directive explicitly prohibits surrogate advertisements and indirect promotional strategies that may mislead consumers.

It also reinforces that these medicines are strictly prescription-only and should not be promoted for off-label use. The CDSCO has warned that violations of these norms may invite regulatory action, including penalties.

Read More: Lupin, Zydus Partner to Co-Market Semaglutide Injection for Diabetes in India.

Conclusion

The CDSCO’s intensified oversight reflects growing concerns over the misuse and unauthorised sale of GLP-1-based weight-loss drugs. Inspections across 49 entities have revealed gaps in compliance related to both distribution and promotion practices.

Regulatory advisories and enforcement actions aim to strengthen oversight mechanisms and ensure patient safety. These developments highlight the importance of strict adherence to prescription norms in the pharmaceutical sector.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.